The conjugate avelumab-IR700 achieved adequate tumor TBRs as shown in Figure 2, indicating that it may be practical for clinical application during surgical or endoscopic procedures because of its high TBR on the PD-L1 expressing tumors. Here, CD274 is linked to neoplasm.